Neuroprotective effect of 3-oxo-3-p-tolyl-propyl-chromane-4-one in conditions of experimental ischemia-reperfusion of the brain

The treatment of acute cerebral circulatory disorders and, in particular, ischemic stroke is a complex interdisciplinary task. One of the directions of therapy for ischemic stroke may be the use of neuroprotectors, pharmacologically active compounds that prevent the alteration of cerebral cells during the manifestation of the process of ischemic brain damage. The aim of the study was to experimentally analyze the neuroprotective potential of 3-oxo-3-p-tolyl-propyl-chromene-4-one in laboratory animals with ischemic reperfusion injury of the brain. Cerebral ischemia-reperfusion was modeled on Wistar rats by the method of filamentous occlusion of the middle cerebral artery. The range of analyzed doses for the tested object was selected as follows: 15 mg/kg, 30 mg/kg, 45 mg/kg and 60 mg/kg. The reference was ethylmethylhydroxypyridine succinate at a dose of 50 mg/kg. This study demonstrated that when the studied object, 3–oxo-3-p-tolyl-propyl-chromene-4-one, was administered to animals at doses of 30 mg/kg, 45 mg/kg and 60 mg/kg, an increase in the activity of the mitochondrial enzymes succinate dehydrogenase and cytochrome c oxidase was observed, while the indicators the groups that are receiving the test substance did not differ from those of the rats treated by the reference. Also, against the background of the administration of the studied compound and the reference agent, a decrease in the concentration of apoptosis-inducing factor and mitochondrial hydrogen peroxide was noted, in comparison with the indicators of the group of untreated rats. The obtained data indicate the presence of 3-oxo-3-p-tolyl-propyl-chromene-4-one neuroprotective activity comparable to that of ethylmethylhydroxypyridine succinate, which makes this compound promising for further study as a neuroprotector used in conditions of ischemic stroke.

1. Virani S. S., Alonso A., Benjamin E. J., Bittencourt M. S., Callaway C. W., Carson A. P., Chamberlain A. M., Chang A. R., Cheng S., Delling F. N. , Djousse L., Elkind M. S. V., Ferguson J. F., Fornage M., Khan S. S., Kissela B. M., Knutson K. L., Kwan T. W., Lackland D. T., Lewis T. T., Lichtman J. H., Longenecker C. T., Loop M. S., Lutsey P. L., Martin S. S., Matsushita K., Moran A. E., Mussolino M. E., Perak A. M., Rosamond W. D., Roth G. A., Sampson U. K. A., Satou G. M., Schroeder E. B., Shah S. H., Shay C. M., Spartano N. L., Stokes A., Tirschwell D. L., VanWagner L. B., Tsao C. W. Heart disease and stroke Statistics-2020 update: a report from the American heart association // Circulation. 2020. 141 (9). e139–e596. DOI: 10.1161/CIR.0000000000000757

2. Andone S., Bajko Z., Motataianu A., Maier S., Barcutean L., Balasa R. Neuroprotection in stroke-focus on the renin-angiotensin system: a systematic review // International journal of molecular sciences (IJMS). 2022. 23 (7). 3876. DOI: 10.3390/ijms23073876

3. Haupt M., Gerner S. T., Bähr M., Doeppner T. R. Neuroprotective strategies for ischemic stroke-future perspectives // International Journal of Molecular Sciences (IJMS). 2023. 24 (5). 4334. DOI: 10.3390/ijms24054334

4. Ballarin B., Tymianski M. Discovery and development of NA-1 for the treatment of acute ischemic stroke // Acta pharmacologica sinica. 2018. 39 (5). 661–668. DOI: 10.1038/aps.2018.5

5. Chen W., Zhang H., Li Z., Deng Q., Wang M., Chen Y., Zhang Y. Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke // BMC Neurology. 2024. 24 (1). 209. DOI: 10.1186/s12883-024-03712-1

6. Leonard M. G., Briyal S., Gulati A. Endothelin B receptor agonist, IRL-1620, provides long-term neuroprotection in cerebral ischemia in rats // Brain research. 2012. 1464.14–23. DOI: 10.1016/j.brainres.2012.05.005

7. Ranjan A. K., Briyal S., Gulati A. Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke // Scientific reports.10 (1). 12737. DOI: 10.1038/s41598-020-69673-w

8. Nhu N. T., Xiao S. Y., Liu Y., Kumar V. B., Cui Z. Y., Lee S. D. Neuroprotective effects of a small mitochondrially-targeted tetrapeptide elamipretide in neurodegeneration // Frontiers in integrative neuroscience. 2022. 15. 747901. DOI: 10.3389/fnint.2021.747901

9. Liu A., Hu J., Yang T.-S., Wang C., Yang J., Huang Х., Chang B., Huangfu L., Yu W., Zhang L. Neuroprotective strategies for stroke by natural products: advances and perspectives // Current neuropharmacology. 2023. 21 (11). 2283–2309. DOI: 10.2174/1570159X21666230717144752

10. Volchegorskij I. A., Rassohina L. M., Miroshnichenko I. Yu. Cerebroprotective effects of emoxipine, reamberin and mexidol in alloxan diabetes // Bulletin of experimental biology and medicine. 2013. 155 (1). 63–70. (In Russian).

11. Pozdnyakov D. I. Metabolic effects of 3-substituted chromone derivatives in experimental chronic traumatic conditions // Science and innovations in medicine. 2022. 7 (3). 206–211. DOI: 10.35693/2500-1388-2022-7-3-206-211 (In Russian).

12. Directive 2010/63/EU of the European Parliament and of the Council of the European Union on the protection of animals used for scientific purposes: transl. from English / Rus-LASA, NP "Association of Specialists in working with laboratory animals", working group on translations and publication of thematic literature. St. Petersburg, 2012. 48 p. (In Russian).

13. Longa E. Z., Weinstein P. R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats // Stroke. 1989. 20 (1). 84–91. DOI: 10.1161/01.str.20.1.84

14. Shabanova N. B., Gerashchenko A. D., Lysenko T. A., Voronkov A. V. Antioxidant, antiradical, chelating properties of mexidol and pyrimidine derivative PIR-4 in conditions of experimental cerebral ischemia of the rat brain // Vestnik of the Smolensk state medical academy. 2021. 20 (4). 5–11. DOI: 10.37903/vsgma.2021.4.1 (In Russian).

15. Li Y., D'Aurelio M., Deng J.–H., Park J.-S., Manfredi G., Hu P., Lu J., Bai Y. An assembled complex IV maintains the stability and activity of complex I in mammalian mitochondria // Journal of biological chemistry. 282 (24). 17557–17562. DOI: 10.1074/jbc.M701056200

16. Wang H., Huwaimel B., Verma K., Miller J., Germain T. M., Kinarivala N., Pappas D., Brookes P. S., Trippier P. C. Synthesis and antineoplastic evaluation of mitochondrial complex II (succinate dehydrogenase) inhibitors derived from Atpenin A5 // ChemMedChem. 2017. 12 (13). 1033–1044. DOI: 10.1002/cmdc.201700196

17. Hasler G., Inta D. Emerging perspectives on neuroprotection // Psychotherapy and psychosomatics. 2024. 93 (5). 285–291. DOI: 10.1159/000540032

18. Yang J.-L., Mukda S., Chen S.–D. Diverse roles of mitochondria in ischemic stroke // Redox biology. 2018. 16. 263–275. DOI: 10.1016/j.redox.2018.03.002

19. An H., Zhou B., Ji X. Mitochondrial quality control in acute ischemic stroke // Journal of cerebral blood flow and metabolism: official journal of the international society of cerebral blood flow and metabolism. 2021. 41 (12). 3157–3170. DOI: 10.1177/0271678X211046992

20. Li Y., Wang P., Way J., Fan R., Zuo Y., Shi M., Wu H., Zhou M., Lin J., Wu M., Feng X., Huang Z. Inhibition of Drp1 by Mdivi-1 attenuates cerebral ischemic injury via inhibition of the mitochondria–dependent apoptotic pathway after cardiac arrest // Neuroscience. 2015. 311. 67–74. DOI: 10.1016/j.neuroscience.2015.10.020

21. Zhou X., Wang H.-Y., Wu B., Cheng C.-Y., Xiao W., Wang Z.-Z., Yang Y.–Y., Li P., Yang H. Ginkgolide K attenuates neuronal injury after ischemic stroke by inhibiting mitochondrial fission and GSK-3β-dependent increases in mitochondrial membrane permeability // Oncotarget. 2017. 8 (27). 44682–44693. DOI: 10.18632/oncotarget.17967

22. Mehta P., Pawar A., Mahadik K., Bothiraja C. Emerging novel drug delivery strategies for bioactive flavonol fisetin in biomedicine // Biomedicine & Pharmacotherapy. 2018. 106. 1282–1291. DOI: 10.1016/j.biopha.2018.07.079